This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dong, Y.
Right arrow Articles by Drlica, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dong, Y.
Right arrow Articles by Drlica, K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 1999, p. 1756-1758, Vol. 43, No. 7
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Effect of Fluoroquinolone Concentration on Selection of Resistant Mutants of Mycobacterium bovis BCG and Staphylococcus aureusdagger

Yuzhi Dong,1 Xilin Zhao,1 John Domagala,2 and Karl Drlica1,*

Public Health Research Institute, New York, New York 10016,1 and Parke-Davis Pharmaceutical Research Division, Warner Lambert Company, Ann Arbor, Michigan 481052

Received 7 December 1998/Returned for modification 25 January 1999/Accepted 12 April 1999


    ABSTRACT
Top
Abstract
Text
References

When Mycobacterium bovis BCG and Staphylococcus aureus were plated on agar containing increasing concentrations of fluoroquinolone, colony numbers exhibited a sharp drop, followed by a plateau and a second sharp drop. The plateau region correlated with the presence of first-step resistant mutants. Mutants were not recovered at concentrations above those required for the second sharp drop, thereby defining a mutant prevention concentration (MPC). A C-8-methoxy group lowered the MPC for an N-1-cyclopropyl fluoroquinolone.


    TEXT
Top
Abstract
Text
References

Fluoroquinolones are potent antibacterial agents that have DNA gyrase and DNA topoisomerase IV as their intracellular targets (for a review, see reference 4). Since these targets are essential enzymes that are conserved among bacterial species, fluoroquinolones are effective against a broad range of bacteria. However, many pathogens, such as Staphylococcus aureus, Pseudomonas aeruginosa, and Neisseria gonorrhoeae, readily acquire resistance through the stepwise accumulation of mutations in genes encoding the two topoisomerases (for a review, see references 4 and 9). Resistance can severely limit the clinical usefulness of fluoroquinolones, and many new derivatives have been synthesized in an attempt to find more effective compounds (for examples, see references 8, 12, and 13). We recently noticed that several new compounds differ in their abilities to restrict the selection of resistant mutants (3, 15). Since this restriction was not readily predicted by the standard bacteriostatic assay for potency (15), it was not obvious how fluoroquinolone structure influences the development of resistant bacterial populations. To help define the relationships between fluoroquinolone structure and resistance, we examined the effect of fluoroquinolone concentration on the recovery of resistant mutants. As described below, we observed a complex relationship that depended on the bacterial species being tested and on the structure of the fluoroquinolone.

Two bacterial species were examined for colony formation on fluoroquinolone-containing agar. One organism, Mycobacterium bovis BCG, has DNA gyrase as its primary fluoroquinolone target (3), while the other, S. aureus, has DNA topoisomerase IV as its primary target (1, 5, 6, 10). M. bovis BCG was cultured with Middlebrook 7H9 liquid medium enriched with 10% albumin-dextrose complex and 0.05% Tween 80; Middlebrook 7H10 agar plates were used for single-colony isolation (7). S. aureus was cultured in CY liquid medium and grown into colonies on GL agar plates (11). Both organisms were grown to stationary phase in liquid medium, concentrated by centrifugation (5,000 × g for 25 min), and then resuspended in fresh medium. Aliquots containing up to 1011 cells were applied to agar plates containing various fluoroquinolone concentrations; plates were incubated at 37°C for 30 to 42 days for M. bovis BCG and 2 days for S. aureus. All colonies regrew on agar containing the selecting fluoroquinolone. Fluoroquinolones were obtained from Sigma Biochemical Corp. (norfloxacin), Miles Laboratories (ciprofloxacin), and Parke-Davis Pharmaceutical Co. (PD161148 and PD160793). Fluoroquinolone structures are shown in Fig. 1.


View larger version (19K):
[in this window]
[in a new window]
  		FIG. 1.   Fluoroquinolone structures. The arrow shown in PD161148 indicates the C-8 position.

As the fluoroquinolone concentration in agar plates increased, two sharp declines were observed in the fractions of CFU recovered when wild-type cells were applied to plates (Fig. 2). The first decline, which occurred around the MIC for 99% of input cells (MIC99; Fig. 2), we attributed to the inhibition of wild-type cell growth. Above the MIC, a concentration range existed in which the recovery of CFU declined more gradually. The concentration range spanned by this part of the response, the plateau region, varied from one fluoroquinolone to another. For example, the region occurred over a much narrower concentration range for a C-8-methoxy compound (PD161148) than for its C-8-H derivative (PD160793) or for ciprofloxacin (Fig. 2). Since the C-8-methoxy compound is more active than its C-8-H derivative or ciprofloxacin against first-step mutants (3, 14, 15), we attributed the plateau region of the curve to the presence of resistant mutants. As shown in Table 1, a nucleotide sequence analysis of DNA from colonies recovered from ciprofloxacin-containing agar revealed alterations in the quinolone resistance-determining region of GyrA (M. bovis BCG) and ParC (GrlA; S. aureus). In the case of S. aureus, some colonies that were recovered at low concentrations of ciprofloxacin lacked an expected mutation in the quinolone resistance-determining region of ParC. Genes associated with resistance in these colonies have not yet been identified.


View larger version (21K):
[in this window]
[in a new window]
  		FIG. 2.   Effect of fluoroquinolone concentration on selection of resistant mutants. M. bovis BCG isolate KD1295 (A) and S. aureus MT5 (B) were plated on agar containing the indicated concentrations of PD161148, a C-8-methoxy compound (open squares), PD160793, a C-8-H derivative (filled squares), or ciprofloxacin (open circles). Panel A also shows the responses of the M. bovis BCG first-step mutant CX1 (3) to ciprofloxacin (filled circles); in panel B, half-filled squares show the responses of a first-step parC (Cipr) mutant of S. aureus (strain KD1806) to treatment with the indicated concentrations of PD160793. After incubation to allow growth, colonies were counted, and the fraction of the input number was determined. In the experiments shown, up to 1011 cells were applied to agar plates. The MIC99 for each compound is indicated by arrows. Small arrowheads on the abscissa indicate the MPC1010 for the C-8-methoxy compound (m), C-8-H compound (h), and ciprofloxacin (c).

                              
View this table:
[in this window]
[in a new window]
  		TABLE 1.   Resistance alleles selected by plating on ciprofloxacin-containing agar

The second sharp drop in mutant recovery (Fig. 2) occurred once the fluoroquinolone concentration was sufficient to block the growth of first-step mutants. For example, the MIC for first-step mutants of M. bovis BCG and S. aureus occurred at about the same fluoroquinolone concentration as the second drop in mutant recovery when wild-type cells were challenged (Fig. 2). The plateau region seen with M. bovis BCG and S. aureus differed in two ways. First, the plateau extended over a greater range of fluoroquinolone concentration for M. bovis BCG. This observation is consistent with the greater difference in quinolone sensitivity between wild-type cells and first-step mutants for M. bovis BCG (13- to 90-fold [3]) than for S. aureus (about 2-fold [14]). Second, the number of mutants recovered in the plateau region was 4 orders of magnitude higher for S. aureus (Fig. 2), indicating that the S. aureus population contained many more first-step mutants. Differences in growth rates and in the target compositions of the two species may contribute to these findings: S. aureus contains both topoisomerase IV and gyrase, while M. bovis BCG probably contains only the latter (an examination of the genomic nucleotide sequence of M. tuberculosis, a closely related organism, failed to identify genes likely to encode topoisomerase IV [2]).

The addition of a C-8-methoxy group to an N-1-cyclopropyl fluoroquinolone lowered the concentration at which the second drop occurred and shortened the plateau region. The effect of adding the methoxy group was about a 10-fold decrease in the case of M. bovis BCG and about a 2.5-fold decrease for S. aureus (Fig. 2). These data suggest that the methoxy group lowers the concentration required to prevent mutants from being recovered, a parameter we call the mutant prevention concentration (MPC). The MPC is estimated by determining the minimal antibiotic concentration that results in recovery of no mutants when large numbers of cells are applied to antibiotic-containing agar plates (the use of large numbers of cells, on the order of 1010 for M. bovis BCG, ensures that the restrictive antibiotic concentration blocks the growth of first-step mutants). The MPC depends on the number of cells applied; consequently, a subscript is added to indicate the number of cells tested (e.g., MPC1010 for 1010 cells applied to plates). This qualification allows data from different organisms, antibiotics, and laboratories to be compared. As with MIC determination, fluoroquinolone concentrations in agar plates can be standardized by having successive concentrations differ by twofold. When smaller increments are used, the MPC can be expressed as a range between the highest concentration at which mutants are recovered and the lowest at which they are not. For example, we performed five independent experiments with S. aureus and obtained the following values for the MPC1010 of ciprofloxacin, expressed as the range defined above: 0.7 to 0.8, 0.8 to 0.9, 0.6 to 0.7, 0.8 to 0.9, and 0.8 to 0.9 µg/ml. When only the upper number in each range is considered, the standard deviation was about 10%. Fluoroquinolones that display superior bacteriostatic activity (low MIC) are often quite effective at preventing the selection of resistant mutants (low MPC). However, the relationship is not proportional (Table 2).

                              
View this table:
[in this window]
[in a new window]
  		TABLE 2.   Relationship between MIC and MPC in S. aureus

In conclusion, plots comparing antibiotic concentration to the fraction of input cells recovered as resistant colonies discriminate among compounds and simplify identification of those compounds least likely to allow bacterial populations to become resistant. Such a measurement requires no information on the nature of the resistance alleles. The assay can be simplified by determining the minimum concentration that allows no mutants to be recovered when large numbers of cells are applied to agar plates. This concentration, the MPC, should be useful for establishing therapeutic antibiotic regimens, particularly for the long-term treatment of immunodeficient patients.


    ACKNOWLEDGMENTS

We thank M. Gennaro, S. Kayman, B. Kreiswirth, and I. Smith for critical comments on the manuscript. We also thank D. Hooper for providing wild-type S. aureus strain MT5.

This work was supported by NIH grant AI35257.


    FOOTNOTES

* Corresponding author. Mailing address: Public Health Research Institute, 455 First Ave., New York, NY 10016. Phone: (212) 578-0830. Fax: (212) 578-0804. E-mail: drlica{at}phri.nyu.edu.

dagger Publication 65 from the Public Health Research Institute TB Center.


    REFERENCES
Top
Abstract
Text
References

1. Blanche, F., B. Cameron, F.-X. Bernard, L. Maton, B. Manse, L. Ferrero, N. Ratet, C. Lecoq, A. Goniot, D. Bisch, and J. Crouzet. 1996. Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases. Antimicrob. Agents Chemother. 40:2714-2720[Abstract].
2. Cole, S. T., R. Brosch, J. Parkhill, T. Garnier, C. Churcher, D. Harris, S. Gordon, K. Eiglmeier, S. Gas, C. E. Barry, F. Tekaia, K. Babcock, D. Basham, D. Brown, T. Chillingworth, R. Connor, R. Davies, K. Devlin, T. Feltwell, S. Gentles, N. Hamlin, S. Holroyd, T. Hornsby, K. Jagels, and B. Barrell. 1998. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393:537-544[Medline].
3. Dong, Y., C. Xu, X. Zhao, J. Domagala, and K. Drlica. 1998. Fluoroquinolone action against mycobacteria: effects of C-8 substituents on growth, survival, and resistance. Antimicrob. Agents Chemother. 42:2978-2984[Abstract/Free Full Text].
4. Drlica, K., and X. Zhao. 1997. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 61:377-392[Abstract].
5. Ferrero, L., B. Cameron, and J. Crouzet. 1995. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob. Agents Chemother. 39:1554-1558[Abstract].
6. Ferrero, L., B. Cameron, B. Manse, D. Lagneaux, J. Crouzet, A. Famechon, and F. Blanche. 1994. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase. IV. A primary target of fluoroquinolones. Mol. Microbiol. 13:641-653[Medline].
7. Jacobs, W. R., G. V. Kalpana, J. D. Cirillo, L. Pascopella, S. B. Snapper, R. A. Udani, W. Jones, R. G. Barletta, and B. R. Bloom. 1991. Genetic systems in mycobacteria. Methods Enzymol. 204:537-555[Medline].
8. Klopman, G., D. Fercu, T. E. Renau, and M. R. Jacobs. 1996. N-1-tert-butyl-substituted quinolones: in vitro anti-Mycobacterium avium activities and structure-activity relationship studies. Antimicrob. Agents Chemother. 40:2637-2643[Abstract].
9. Nakamura, S. 1997. Mechanisms of quinolone resistance. J. Infect. Chemother. 3:128-138.
10. Ng, E. Y., M. Trucksis, and D. C. Hooper. 1996. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus. Antimicrob. Agents Chemother. 40:1881-1888[Abstract].
11. Novick, R. P., and R. Brodsky. 1972. Studies on plasmid replication. I. Plasmid incompatibility and establishment in Staphylococcus aureus. J. Mol. Biol. 68:285-302[Medline].
12. Renau, T. E., J. W. Gage, J. A. Dever, G. E. Roland, E. T. Joannides, M. A. Shapiro, J. P. Sanchez, S. J. Gracheck, J. M. Domagala, M. R. Jacobs, and R. C. Reynolds. 1996. Structure-activity relationships of quinolone agents against mycobacteria: effect of structural modifications at the 8 position. Antimicrob. Agents Chemother. 40:2363-2368[Abstract].
13. Renau, T. E., J. P. Sanchez, J. W. Gage, J. A. Dever, M. A. Shapiro, S. J. Gracheck, and J. M. Domagala. 1996. Structure-activity relationships of the quinolone antibacterials against mycobacteria: effect of structural changes at N1 and C7. J. Med. Chem. 39:729-735[Medline].
14. Zhao, X., J.-Y. Wang, C. Xu, Y. Dong, J. Zhou, J. Domagala, and K. Drlica. 1998. Killing of Staphylococcus aureus by C-8-methoxy fluoroquinolones. Antimicrob. Agents Chemother. 42:956-958[Abstract/Free Full Text].
15. Zhao, X., C. Xu, J. Domagala, and K. Drlica. 1997. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc. Natl. Acad. Sci. USA 94:13991-13996[Abstract/Free Full Text].

Antimicrobial Agents and Chemotherapy, July 1999, p. 1756-1758, Vol. 43, No. 7
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Allen, G. P., Hankins, C. D. (2009). Evaluation of the mutant selection window for fluoroquinolones against Neisseria gonorrhoeae. J Antimicrob Chemother 64: 359-363 [Abstract] [Full Text]  
  • Ciolino, J. B., Hoare, T. R., Iwata, N. G., Behlau, I., Dohlman, C. H., Langer, R., Kohane, D. S. (2009). A Drug-Eluting Contact Lens. IOVS 50: 3346-3352 [Abstract] [Full Text]  
  • Becnel Boyd, L., Maynard, M. J., Morgan-Linnell, S. K., Horton, L. B., Sucgang, R., Hamill, R. J., Jimenez, J. R., Versalovic, J., Steffen, D., Zechiedrich, L. (2009). Relationships among Ciprofloxacin, Gatifloxacin, Levofloxacin, and Norfloxacin MICs for Fluoroquinolone-Resistant Escherichia coli Clinical Isolates. Antimicrob. Agents Chemother. 53: 229-234 [Abstract] [Full Text]  
  • Cairns, B. J., Payne, R. J. H. (2008). Bacteriophage Therapy and the Mutant Selection Window. Antimicrob. Agents Chemother. 52: 4344-4350 [Abstract] [Full Text]  
  • German, N., Malik, M., Rosen, J. D., Drlica, K., Kerns, R. J. (2008). Use of Gyrase Resistance Mutants To Guide Selection of 8-Methoxy-Quinazoline-2,4-Diones. Antimicrob. Agents Chemother. 52: 3915-3921 [Abstract] [Full Text]  
  • Michel, J.-B., Yeh, P. J., Chait, R., Moellering, R. C. Jr., Kishony, R. (2008). Drug interactions modulate the potential for evolution of resistance. Proc. Natl. Acad. Sci. USA 105: 14918-14923 [Abstract] [Full Text]  
  • Zhao, X., Drlica, K. (2008). A unified anti-mutant dosing strategy. J Antimicrob Chemother 62: 434-436 [Abstract] [Full Text]  
  • Okumura, R., Hirata, T., Onodera, Y., Hoshino, K., Otani, T., Yamamoto, T. (2008). Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae. J Antimicrob Chemother 62: 98-104 [Abstract] [Full Text]  
  • Nomura, K., Morikawa, N., Ikawa, K., Ikeda, K., Fujimoto, Y., Shimizu, D., Taniguchi, K., Shimura, K., Kanbayashi, Y., Komori, T., Matsumoto, Y., Fujita, N., Shimazaki, C., Taniwaki, M. (2008). Optimized dosage and frequency of cefozopran for patients with febrile neutropenia based on population pharmacokinetic and pharmacodynamic analysis. J Antimicrob Chemother 61: 892-900 [Abstract] [Full Text]  
  • Oonishi, Y., Mitsuyama, J., Yamaguchi, K. (2007). Effect of GrlA mutation on the development of quinolone resistance in Staphylococcus aureus in an in vitro pharmacokinetic model. J Antimicrob Chemother 60: 1030-1037 [Abstract] [Full Text]  
  • Homma, T., Hori, T., Sugimori, G., Yamano, Y. (2007). Pharmacodynamic Assessment Based on Mutant Prevention Concentrations of Fluoroquinolones To Prevent the Emergence of Resistant Mutants of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51: 3810-3815 [Abstract] [Full Text]  
  • Goessens, W. H. F., Mouton, J. W., ten Kate, M. T., Bijl, A. J., Ott, A., Bakker-Woudenberg, I. A. J. M. (2007). Role of ceftazidime dose regimen on the selection of resistant Enterobacter cloacae in the intestinal flora of rats treated for an experimental pulmonary infection. J Antimicrob Chemother 59: 507-516 [Abstract] [Full Text]  
  • Goldstein, F. (2007). The potential clinical impact of low-level antibiotic resistance in Staphylococcus aureus. J Antimicrob Chemother 59: 1-4 [Abstract] [Full Text]  
  • Ba, B. B., Arpin, C., Vidaillac, C., Chausse, A., Saux, M.-C., Quentin, C. (2006). Activity of Gatifloxacin in an In Vitro Pharmacokinetic-Pharmacodynamic Model against Staphylococcus aureus Strains either Susceptible to Ciprofloxacin or Exhibiting Various Levels and Mechanisms of Ciprofloxacin Resistance.. Antimicrob. Agents Chemother. 50: 1931-1936 [Abstract] [Full Text]  
  • Olofsson, S. K., Marcusson, L. L., Komp Lindgren, P., Hughes, D., Cars, O. (2006). Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration. J Antimicrob Chemother 57: 1116-1121 [Abstract] [Full Text]  
  • Drlica, K., Zhao, X., Blondeau, J. M., Hesje, C. (2006). Low Correlation between MIC and Mutant Prevention Concentration. Antimicrob. Agents Chemother. 50: 403-404 [Full Text]  
  • Strahilevitz, J., Truong-Bolduc, Q. C., Hooper, D. C. (2005). DX-619, a Novel Des-Fluoro(6) Quinolone Manifesting Low Frequency of Selection of Resistant Staphylococcus aureus Mutants: Quinolone Resistance beyond Modification of Type II Topoisomerases. Antimicrob. Agents Chemother. 49: 5051-5057 [Abstract] [Full Text]  
  • Wetzstein, H.-G. (2005). Comparative Mutant Prevention Concentrations of Pradofloxacin and Other Veterinary Fluoroquinolones Indicate Differing Potentials in Preventing Selection of Resistance. Antimicrob. Agents Chemother. 49: 4166-4173 [Abstract] [Full Text]  
  • Marcusson, L. L., Olofsson, S. K., Lindgren, P. K., Cars, O., Hughes, D. (2005). Mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of Escherichia coli. J Antimicrob Chemother 55: 938-943 [Abstract] [Full Text]  
  • Strahilevitz, J., Hooper, D. C. (2005). Dual Targeting of Topoisomerase IV and Gyrase To Reduce Mutant Selection: Direct Testing of the Paradigm by Using WCK-1734, a New Fluoroquinolone, and Ciprofloxacin. Antimicrob. Agents Chemother. 49: 1949-1956 [Abstract] [Full Text]  
  • Hermsen, E. D., Hovde, L. B., Konstantinides, G. N., Rotschafer, J. C. (2005). Mutant Prevention Concentrations of ABT-492, Levofloxacin, Moxifloxacin, and Gatifloxacin against Three Common Respiratory Pathogens. Antimicrob. Agents Chemother. 49: 1633-1635 [Abstract] [Full Text]  
  • Campion, J. J., McNamara, P. J., Evans, M. E. (2004). Evolution of Ciprofloxacin-Resistant Staphylococcus aureus in In Vitro Pharmacokinetic Environments. Antimicrob. Agents Chemother. 48: 4733-4744 [Abstract] [Full Text]  
  • Epstein, B. J, Gums, J. G, Drlica, K. (2004). The Changing Face of Antibiotic Prescribing: The Mutant Selection Window. The Annals of Pharmacotherapy 38: 1675-1682 [Abstract] [Full Text]  
  • Li, X., Mariano, N., Rahal, J. J., Urban, C. M., Drlica, K. (2004). Quinolone-Resistant Haemophilus influenzae in a Long-Term-Care Facility: Nucleotide Sequence Characterization of Alterations in the Genes Encoding DNA Gyrase and DNA Topoisomerase IV. Antimicrob. Agents Chemother. 48: 3570-3572 [Abstract] [Full Text]  
  • Maeda, Y., Kiba, A., Ohnishi, K., Hikichi, Y. (2004). Implications of Amino Acid Substitutions in GyrA at Position 83 in Terms of Oxolinic Acid Resistance in Field Isolates of Burkholderia glumae, a Causal Agent of Bacterial Seedling Rot and Grain Rot of Rice. Appl. Environ. Microbiol. 70: 5613-5620 [Abstract] [Full Text]  
  • Croisier, D., Etienne, M., Bergoin, E., Charles, P.-E., Lequeu, C., Piroth, L., Portier, H., Chavanet, P. (2004). Mutant Selection Window in Levofloxacin and Moxifloxacin Treatments of Experimental Pneumococcal Pneumonia in a Rabbit Model of Human Therapy. Antimicrob. Agents Chemother. 48: 1699-1707 [Abstract] [Full Text]  
  • Rodriguez, J. C., Cebrian, L., Lopez, M., Ruiz, M., Jimenez, I., Royo, G. (2004). Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis. J Antimicrob Chemother 53: 441-444 [Abstract] [Full Text]  
  • Cheng, A. F. B., Yew, W. W., Chan, E. W. C., Chin, M. L., Hui, M. M. M., Chan, R. C. Y. (2004). Multiplex PCR Amplimer Conformation Analysis for Rapid Detection of gyrA Mutations in Fluoroquinolone-Resistant Mycobacterium tuberculosis Clinical Isolates. Antimicrob. Agents Chemother. 48: 596-601 [Abstract] [Full Text]  
  • Linde, H.-J., Lehn, N. (2004). Mutant prevention concentration of nalidixic acid, ciprofloxacin, clinafloxacin, levofloxacin, norfloxacin, ofloxacin, sparfloxacin or trovafloxacin for Escherichia coli under different growth conditions. J Antimicrob Chemother 53: 252-257 [Abstract] [Full Text]  
  • Lu, T., Drlica, K. (2003). In vitro activity of C-8-methoxy fluoroquinolones against mycobacteria when combined with anti-tuberculosis agents. J Antimicrob Chemother 52: 1025-1028 [Abstract] [Full Text]  
  • Paladino, J. A., Sunderlin, J. L., Forrest, A., Schentag, J. J. (2003). Characterization of the onset and consequences of pneumonia due to fluoroquinolone-susceptible or -resistant Pseudomonas aeruginosa. J Antimicrob Chemother 52: 457-463 [Abstract] [Full Text]  
  • Allen, G. P., Kaatz, G. W., Rybak, M. J. (2003). Activities of Mutant Prevention Concentration-Targeted Moxifloxacin and Levofloxacin against Streptococcus pneumoniae in an In Vitro Pharmacodynamic Model. Antimicrob. Agents Chemother. 47: 2606-2614 [Abstract] [Full Text]  
  • Drlica, K. (2003). The mutant selection window and antimicrobial resistance. J Antimicrob Chemother 52: 11-17 [Abstract] [Full Text]  
  • Lu, T., Zhao, X., Li, X., Hansen, G., Blondeau, J., Drlica, K. (2003). Effect of chloramphenicol, erythromycin, moxifloxacin, penicillin and tetracycline concentration on the recovery of resistant mutants of Mycobacterium smegmatis and Staphylococcus aureus. J Antimicrob Chemother 52: 61-64 [Abstract] [Full Text]  
  • Ince, D., Zhang, X., Hooper, D. C. (2003). Activity of and Resistance to Moxifloxacin in Staphylococcus aureus. Antimicrob. Agents Chemother. 47: 1410-1415 [Abstract] [Full Text]  
  • Zhao, X., Eisner, W., Perl-Rosenthal, N., Kreiswirth, B., Drlica, K. (2003). Mutant Prevention Concentration of Garenoxacin (BMS-284756) for Ciprofloxacin-Susceptible or -Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 47: 1023-1027 [Abstract] [Full Text]  
  • Kishii, R., Takei, M., Fukuda, H., Hayashi, K., Hosaka, M. (2003). Contribution of the 8-Methoxy Group to the Activity of Gatifloxacin against Type II Topoisomerases of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 47: 77-81 [Abstract] [Full Text]  
  • Li, X., Zhao, X., Drlica, K. (2002). Selection of Streptococcus pneumoniae Mutants Having Reduced Susceptibility to Moxifloxacin and Levofloxacin. Antimicrob. Agents Chemother. 46: 522-524 [Abstract] [Full Text]  
  • Lu, T., Zhao, X., Li, X., Drlica-Wagner, A., Wang, J.-Y., Domagala, J., Drlica, K. (2001). Enhancement of Fluoroquinolone Activity by C-8 Halogen and Methoxy Moieties: Action against a Gyrase Resistance Mutant of Mycobacterium smegmatis and a Gyrase-Topoisomerase IV Double Mutant of Staphylococcus aureus. Antimicrob. Agents Chemother. 45: 2703-2709 [Abstract] [Full Text]  
  • Ince, D., Hooper, D. C. (2001). Mechanisms and Frequency of Resistance to Gatifloxacin in Comparison to AM-1121 and Ciprofloxacin in Staphylococcus aureus. Antimicrob. Agents Chemother. 45: 2755-2764 [Abstract] [Full Text]  
  • Nash, K. A. (2001). Effect of Drug Concentration on Emergence of Macrolide Resistance in Mycobacterium avium. Antimicrob. Agents Chemother. 45: 1607-1614 [Abstract] [Full Text]  
  • O'Neill, A. J., Chopra, I., Martínez, J. L., Baquero, F. (2001). Use of Mutator Strains for Characterization of Novel Antimicrobial Agents. Antimicrob. Agents Chemother. 45: 1599-1600 [Full Text]  
  • Klepser, M. E., Ernst, E. J., Petzold, C. R., Rhomberg, P., Doern, G. V. (2001). Comparative Bactericidal Activities of Ciprofloxacin, Clinafloxacin, Grepafloxacin, Levofloxacin, Moxifloxacin, and Trovafloxacin against Streptococcus pneumoniae in a Dynamic In Vitro Model. Antimicrob. Agents Chemother. 45: 673-678 [Abstract] [Full Text]  
  • Blondeau, J. M., Zhao, X., Hansen, G., Drlica, K. (2001). Mutant Prevention Concentrations of Fluoroquinolones for Clinical Isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45: 433-438 [Abstract] [Full Text]  
  • Sindelar, G., Zhao, X., Liew, A., Dong, Y., Lu, T., Zhou, J., Domagala, J., Drlica, K. (2000). Mutant Prevention Concentration as a Measure of Fluoroquinolone Potency against Mycobacteria. Antimicrob. Agents Chemother. 44: 3337-3343 [Abstract] [Full Text]  
  • Ince, D., Hooper, D. C. (2000). Mechanisms and Frequency of Resistance to Premafloxacin in Staphylococcus aureus: Novel Mutations Suggest Novel Drug-Target Interactions. Antimicrob. Agents Chemother. 44: 3344-3350 [Abstract] [Full Text]  
  • Negri, M.-C., Lipsitch, M., Blázquez, J., Levin, B. R., Baquero, F. (2000). Concentration-Dependent Selection of Small Phenotypic Differences in TEM beta -Lactamase-Mediated Antibiotic Resistance. Antimicrob. Agents Chemother. 44: 2485-2491 [Abstract] [Full Text]  
  • Dong, Y., Zhao, X., Kreiswirth, B. N., Drlica, K. (2000). Mutant Prevention Concentration as a Measure of Antibiotic Potency: Studies with Clinical Isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 44: 2581-2584 [Abstract] [Full Text]  
  • Fournier, B., Zhao, X., Lu, T., Drlica, K., Hooper, D. C. (2000). Selective Targeting of Topoisomerase IV and DNA Gyrase in Staphylococcus aureus: Different Patterns of Quinolone- Induced Inhibition of DNA Synthesis. Antimicrob. Agents Chemother. 44: 2160-2165 [Abstract] [Full Text]  
  • Lu, T., Zhao, X., Drlica, K. (1999). Gatifloxacin Activity against Quinolone-Resistant Gyrase: Allele-Specific Enhancement of Bacteriostatic and Bactericidal Activities by the C-8-Methoxy Group. Antimicrob. Agents Chemother. 43: 2969-2974 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dong, Y.
Right arrow Articles by Drlica, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dong, Y.
Right arrow Articles by Drlica, K.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»